The short version of GHRH analogue fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-29. Anything still debated is marked as such rather than presented as settled.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
U.S. patent 708,553 – Submarine boat The Submarine: Part II: Construction (1955) is available for free viewing and download at the Internet Archive "The Fleet Type Submarine Online". Archived from the original on 13 October 2007. Retrieved 10 July 2026. Tingle, C. (September 2009). "Submarine Accidents: A 60-Year Statistical Assessment". Journal of Professional Safety. American Society of Safety Engineers: 31–39. Archived from the original on 4 July 2014. Retrieved 10 July 2026.
== Mechanism of action == Streptogramins A and B synergically inhibit cell growth of gram positive, less so gram negative bacteria by inhibiting protein synthesis, but separately they are bacteriostatic. The molecular target of streptogramins is the 23S rRNA. Both streptogramin A and B bind to the P binding site of the 50S ribosome subunit. The type A streptogramin binding causes a conformational change to the 50S subunit, which increases the activity of the type B streptogramin by a 100-fold. Streptogramin B prevents the elongation of protein chains and causes the release of incomplete peptides.
The first studies measuring drugs in biological fluids were carried out to determine possible overdosing as part of the new science of forensic medicine/toxicology. Initially, nonspecific assays were applied to measuring drugs in biological fluids. These were unable to discriminate between the drug and its metabolites; for example, aspirin (c. 1900) and sulfonamides (developed in the 1930s) were quantified by the use of colorimetric assays. Antibiotics were quantified by their ability to inhibit bacterial growth. The 1930s also saw the rise of pharmacokinetics, and as such the desire for more specific assays. Modern drugs are more potent, which has required more sensitive bioanalytical assays to accurately and reliably determine these drugs at lower concentrations. This has driven improvements in technology and analytical methods. Some techniques commonly used in bioanalytical studies include:
FlF2 and FlCl2 are predicted to be more stable than FlH2. Due to relativistic stabilization of flerovium's 7s27p21/2 valence electron configuration, the 0 oxidation state should also be more stable for flerovium than for lead, as the 7p1/2 electrons begin to also have a mild inert pair effect: this stabilization of the neutral state may bring about some similarities between the behavior of flerovium and the noble gas radon. Due to flerovium's expected relative inertness, diatomic compounds FlH and FlF should have lower energies of dissociation than the corresponding lead compounds PbH and PbF. Flerovium(IV) should be even more electronegative than lead(IV); lead(IV) has electronegativity 2.33 on the Pauling scale, though the lead(II) value is only 1.87. Flerovium could be a noble metal. Flerovium(II) should be more stable than lead(II), and halides FlX+, FlX2, FlX−3, and FlX2−4 (X = Cl, Br, I) are expected to form readily. The fluorides would undergo strong hydrolysis in aqueous solution. All flerovium dihalides are expected to be stable; the difluoride being water-soluble. Spin–orbit effects would destabilize the dihydride (FlH2) by almost 2.6 eV (250 kJ/mol). In aqueous solution, the oxyanion flerovite (FlO2−2) would also form, analogous to plumbite. Flerovium(II) sulfate (FlSO4) and sulfide (FlS) should be very insoluble in water, and flerovium(II) acetate (Fl(C2H3O2)2) and nitrate (Fl(NO3)2) should be quite water-soluble.
Gliquidone (INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class. It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).
Sources: en.wikipedia.org
By September 2014, Houthis were said to control parts of the Yemeni capital, Sanaa, including government buildings and a radio station. While Houthi control expanded to the rest of Sanaa, as well as other towns such as Rada', this control was strongly challenged by Al-Qaeda. The Gulf States believed that the Houthis had accepted aid from Iran while Saudi Arabia was aiding their Yemeni rivals. On 20 January 2015, Houthi rebels seized the presidential palace in the capital. President Abdrabbuh Mansur Hadi was in the presidential palace during the takeover but was not harmed. The movement officially took control of the Yemeni government on 6 February, dissolving parliament and declaring its Revolutionary Committee to be the acting authority in Yemen. On 20 March the al-Badr and al-Hashoosh mosques came under suicide attack during midday prayers, and the Islamic State quickly claimed responsibility. The blasts killed 142 Houthi worshippers and wounded more than 351, making it the deadliest terrorist attack in Yemen's history. On 27 March 2015, in response to perceived Houthi threats to Sunni factions in the region, Saudi Arabia along with Bahrain, Qatar, Kuwait, UAE, Egypt, Jordan, Morocco, and Sudan led a gulf coalition airstrike in Yemen. The military coalition included the United States which helped in planning of airstrikes, as well as logistical and intelligence support.
== First generation GcMAF == Gc protein-derived macrophage-activating factor (GcMAF). GcMAF initially conceptualized by Nobuto Yamamoto in 1991, has been researched as a possible cancer treatment. Previous research efforts involved the isolation of Gc protein (1f1f subtype) from human serum through an affinity column modified with 25-hydroxyvitamin D3. GcMAF was enzymatically derived from the isolated Gc protein.
== Research and innovation == BioDuro is involved in developing data-driven and automated workflows intended to accelerate discovery timelines. The company has partnered with technology firms, including Atombeat, to integrate AI-supported peptide-design platforms with high-throughput peptide synthesis and iterative screening workflows. According to the company, these approaches are designed to reduce design–test cycles in peptide and bioconjugate programs; independent evaluation of the platform’s performance is still limited in publicly available literature.
In a survey of the general population, it was found that although many erect penises point upwards, it is common and normal for the erect penis to point nearly vertically upwards or horizontally straight forward or even nearly vertically downwards, all depending on the tension of the suspensory ligament that holds it in position. 37% of healthy men have a penile curve. With 22.2% of men having upwards curvature and 14.8% of men having downwards curvature.
Sources: en.wikipedia.org
=== Other === Escitalopram may reduce premenstrual symptoms in women with premenstrual syndrome and premenstrual dysphoric disorder. It seems to be more effective when taken continuously compared to luteal phase administration. It is also occasionally prescribed off-label for insomnia secondary to a mental disorder, and vasomotor symptoms (hot flashes) associated with menopause.
Codeine-6-glucuronide (C6G) is a major active metabolite of codeine and may be responsible for as much as 60% of the analgesic effects of codeine. C6G exhibits decreased immunosuppressive effects compared to codeine.
These pedestrian zones are part of an effort to combat chronic diseases, including obesity. In an effort to combat the issue, a primary school in Australia instituted a standing classroom in 2013. There is evidence that exercise alone is not sufficient to produce meaningful weight loss, but combining dieting and exercise provide the greatest health benefits and weight loss on the long term.
=== Ligand removal === In many cases, as in various high-temperature catalytic applications of Au, the removal of the capping ligands produces more desirable physicochemical properties. The removal of ligands from colloidal gold while maintaining a relatively constant number of Au atoms per Au NP can be difficult due to the tendency for these bare clusters to aggregate. The removal of ligands is partially achievable by simply washing away all excess capping ligands, though this method is ineffective in removing all capping ligand. More often ligand removal achieved under high temperature or light ablation followed by washing. Alternatively, the ligands can be electrochemically etched off.
== Etymology == The English name "Normans" comes from the French words Normans/Normanz, plural of Normant, modern French normand, which is itself borrowed from Old Low Franconian Nortmann "Northman" or directly from Old Norse Norðmaðr, Latinized variously as Nortmannus, Normannus, or Nordmannus (recorded in Medieval Latin, 9th century) to mean "Norseman, Viking". The 11th century Benedictine monk and historian, Goffredo Malaterra, characterised the Normans thus:
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.